Results 181 to 190 of about 27,657 (222)
A simple and robust reporter-based framework for deep functional characterization of PPARĪ³ mutants.
EndocrinologyBaak R +4 more
europepmc +1 more source
Expert Opinion on Pharmacotherapy, 2001 Type 2 diabetes mellitus is characterised by impaired insulin secretion, diminished peripheral insulin action and increased hepatic glucose production. Clinical trials have indicated that near-normal glucose control may reduce the risk for microvascular and - to a lesser extent - macrovascular complications in Type 2 diabetic patients ...
Wolffenbuttel, B.H.R. +2 more
core +5 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drugs, 1999
Rosiglitazone, a thiazolidinedione antidiabetic agent, improves insulin resistance, a key underlying metabolic abnormality in most patients with type 2 (non-insulin-dependent) diabetes mellitus. In animal models of insulin resistance, rosiglitazone decreased plasma glucose, insulin and triglyceride levels and also attenuated or prevented diabetic ...
J A, Balfour, G L, Plosker
+6 more sources
Rosiglitazone, a thiazolidinedione antidiabetic agent, improves insulin resistance, a key underlying metabolic abnormality in most patients with type 2 (non-insulin-dependent) diabetes mellitus. In animal models of insulin resistance, rosiglitazone decreased plasma glucose, insulin and triglyceride levels and also attenuated or prevented diabetic ...
J A, Balfour, G L, Plosker
+6 more sources
Rosiglitazone reduces urinary albumin excretion in type II diabetes
Journal of Human Hypertension, 2003 This study examines the effect of rosiglitazone on urinary albumin excretion (UAE) in patients with type II diabetes. Urinary albumin: creatinine ratio (ACR) was measured in a 52-week, open-label, cardiac safety study comparing rosiglitazone and ...
George L Bakris, G Viberti, Viberti G
exaly +2 more sources
Drugs, 2005
The thiazolidinedione rosiglitazone and the biguanide metformin are effective antihyperglycaemic agents with different modes of action; rosiglitazone primarily increases insulin sensitivity, whereas metformin primarily reduces hepatic glucose output. Antihyperglycaemic combination therapy is often required to achieve effective glycaemic control.
openaire +2 more sources
The thiazolidinedione rosiglitazone and the biguanide metformin are effective antihyperglycaemic agents with different modes of action; rosiglitazone primarily increases insulin sensitivity, whereas metformin primarily reduces hepatic glucose output. Antihyperglycaemic combination therapy is often required to achieve effective glycaemic control.
openaire +2 more sources